Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axonics, Inc.AXNX · Entity 86004 | Director · Chief Executive Officer | November 15, 2024 | November 15, 2024 |
| BIOLIFE SOLUTIONS INCBLFS · Entity 4614 | Director | July 12, 2021 | July 15, 2021 |
| InspireMD, Inc.NSPR · Entity 7318 | Director | January 14, 2026 | January 16, 2026 |
| KESTRA MEDICAL TECHNOLOGIES, LTD.KMTS · Entity 4686 | Director | September 30, 2026 | October 02, 2026 |
| RxSight, Inc.RXST · Entity 1226 | Director | June 17, 2026 | June 18, 2026 |
| SPECTRUM PHARMACEUTICALS INCSPPI · Entity 111009 | Director | June 20, 2019 | June 21, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axonics, Inc.
Report date November 15, 2024 · Filed November 15, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-11-15 transaction · row 1
1 source rowRow 1 · 2024-11-15 · Disposition to issuer · Disposed 292,731 · Balance 0 F1: Reflects the disposition of the reporting person's shares of the Issuer's common stock, upon the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 8, 2024 (the "Merger Agreement"), among the Issuer, Boston Scientific Corporation ("Parent") and Sadie Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger of Merger Sub with and into the Issuer with the Issuer as the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective time"), each outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive $71.00 in cash, without interest (The "Merger Consideration"). F2: The shares of the Issuer's common stock reported as disposed by the reporting person include restricted stock awards. Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock award granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the Merger Consideration and (b) the aggregate number of shares subject to such restricted stock award, less applicable taxes and authorized deductions. |
| Performance-Based Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-11-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-11-15 · Disposition to issuer · Disposed 31,125 · Balance 0 F3: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of the Issuer's common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to be earned by the reporting person ranged from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total stockholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2025, and provided the reporting person remains in continuous service through January 31, 2025. F4: Pursuant the Merge Agreement, at the Effective Time, each outstanding Performance-Based Restricted Stock Unit granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan for which the market condition is relative total stockholder return, whether vested but unsettled or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the Merger Consideration and (b) the aggregate number of shares underlying such Performance-Based Restricted Stock Unit (based on the actual performance of the relevant peer group as of the Company's fiscal quarter-end immediately preceding the Effective Time and the Merger Consideration as the per share price), less applicable taxes and authorized deductions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.19 · Expires 2029-01-30 | Direct | 0 |
Reported balance
After 2024-11-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-11-15 · Disposition to issuer · Disposed 196,451 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.63 · Expires 2028-03-30 | Direct | 0 |
Reported balance
After 2024-11-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-11-15 · Disposition to issuer · Disposed 106,776 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of the reporting person's shares of the Issuer's common stock, upon the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 8, 2024 (the "Merger Agreement"), among the Issuer, Boston Scientific Corporation ("Parent") and Sadie Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger of Merger Sub with and into the Issuer with the Issuer as the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective time"), each outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive $71.00 in cash, without interest (The "Merger Consideration").
F2: The shares of the Issuer's common stock reported as disposed by the reporting person include restricted stock awards. Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock award granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the Merger Consideration and (b) the aggregate number of shares subject to such restricted stock award, less applicable taxes and authorized deductions.
F3: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of the Issuer's common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to be earned by the reporting person ranged from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total stockholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2025, and provided the reporting person remains in continuous service through January 31, 2025.
F4: Pursuant the Merge Agreement, at the Effective Time, each outstanding Performance-Based Restricted Stock Unit granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan for which the market condition is relative total stockholder return, whether vested but unsettled or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the Merger Consideration and (b) the aggregate number of shares underlying such Performance-Based Restricted Stock Unit (based on the actual performance of the relevant peer group as of the Company's fiscal quarter-end immediately preceding the Effective Time and the Merger Consideration as the per share price), less applicable taxes and authorized deductions.
F5: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions
BIOLIFE SOLUTIONS INC
Report date July 12, 2021 · Filed July 15, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,763 |
Reported balance
After 2021-07-12 transaction · row 1
1 source rowRow 1 · 2021-07-12 · Grant · Acquired 5,000 · Balance 27,763 F1: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan.
InspireMD, Inc.
Report date January 14, 2026 · Filed January 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 92,417 |
Reported balance
After 2026-01-14 transaction · row 1
1 source rowRow 1 · 2026-01-14 · Grant · Acquired 44,030 · Balance 92,417 F1: These shares of common stock represent shares of restricted stock that shall vest on January 14, 2027 (the "One Year Grant Anniversary Date"), subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares of common stock represent shares of restricted stock that shall vest on January 14, 2027 (the "One Year Grant Anniversary Date"), subject to the Reporting Person's continued service.
KESTRA MEDICAL TECHNOLOGIES, LTD.
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 54,790 |
Reported balance
After 2026-09-30 transaction · row 1
1 source rowRow 1 · 2026-09-30 · Sale · Disposed 3,330 · Balance 54,790 F1: The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units. F2: The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $29.2800 to $29.2900. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.
F2: The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $29.2800 to $29.2900. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
RxSight, Inc.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 66,532 |
Reported balance
After 2026-06-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 30,864 · Balance 66,532 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. F2: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date of the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 17, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock.
F2: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date of the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 17, 2026.
SPECTRUM PHARMACEUTICALS INC
Report date June 20, 2019 · Filed June 21, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par valueSEC Table I · non-derivative | Direct | 53,850 |
Reported balance
After 2019-06-20 transaction · row 1
1 source rowRow 1 · 2019-06-20 · Grant · Acquired 10,000 · Balance 53,850 F1: 100% of the restricted shares shall vest on the earlier of (1) June 20, 2020 or (2) the date of the company's 2020 Annual Meeting of Stockholders. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.44 · Expires 2029-06-20 | Direct | 20,000 |
Reported balance
After 2019-06-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-06-20 · Grant · Acquired 20,000 · Balance 20,000 F2: 25% of the option shares vested on June 20, 2019. The remaining option shares shall vest in 25% equal annual amounts on each anniversary date of the grant over three years. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the restricted shares shall vest on the earlier of (1) June 20, 2020 or (2) the date of the company's 2020 Annual Meeting of Stockholders.
F2: 25% of the option shares vested on June 20, 2019. The remaining option shares shall vest in 25% equal annual amounts on each anniversary date of the grant over three years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2022 Filed Feb 4, 2022 02:30 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantPerformance-Based Restricted Stock Units · Derivative | 21,968 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001104 · primarydocument.xml · derivative · entry 5 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,968 Underlying: Common Stock · 21,968 shares Expires not disclosed F4 · security: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2022 and provided the reporting person remains in continuous service through January 31, 2023. F4 · derivative.exercise_price: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2022 and provided the reporting person remains in continuous service through January 31, 2023. F4 · derivative.expiration_date: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2022 and provided the reporting person remains in continuous service through January 31, 2023. Read SEC document |
| January 31, 2022 Filed Feb 4, 2022 02:30 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantCommon Stock | 43,297 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001104 · primarydocument.xml · nonDerivative · entry 1 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,904 Read SEC document |
| September 30, 2021 Filed Feb 16, 2022 00:21 UTC | Axonics, Inc. AXNX · Entity 86004 | GiftCommon Stock | 28,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001499 · primarydocument.xml · nonDerivative · entry 5 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,635 Read SEC document |
| September 09, 2021 Filed Sep 14, 2021 00:59 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 50,000 | $77.11 | $3,855,350.00 |
DisclosureSEC source: 0001562180-21-005938 · primarydocument.xml · nonDerivative · entry 1 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,607 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $77.0935 to $77.1178. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 12, 2021 Filed Jul 15, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-21-016942 · rdgdoc.xml · nonDerivative · entry 1 COHEN RAYMOND W · CIK 0001258288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,763 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan. Read SEC document |
| July 02, 2021 Filed Feb 16, 2022 00:21 UTC | Axonics, Inc. AXNX · Entity 86004 | GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001499 · primarydocument.xml · nonDerivative · entry 4 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,635 Read SEC document |
| June 08, 2021 Filed Jun 11, 2021 01:37 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 33,333 | $60.00 | $1,999,980.00 |
DisclosureSEC source: 0001562180-21-004197 · primarydocument.xml · nonDerivative · entry 1 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,607 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| May 18, 2021 Filed May 21, 2021 01:09 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 32,833 | $55.00 | $1,805,815.00 |
DisclosureSEC source: 0001562180-21-003684 · primarydocument.xml · nonDerivative · entry 1 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,940 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| May 10, 2021 Filed May 13, 2021 00:31 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 2,770 | $54.81 | $151,824.25 |
DisclosureSEC source: 0001562180-21-003441 · primarydocument.xml · nonDerivative · entry 3 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,773 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $54.60 to $55.495. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 10, 2021 Filed May 13, 2021 00:31 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 17,954 | $54.13 | $971,797.95 |
DisclosureSEC source: 0001562180-21-003441 · primarydocument.xml · nonDerivative · entry 2 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,543 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $53.595 to $54.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 10, 2021 Filed May 13, 2021 00:31 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 13,109 | $52.98 | $694,535.79 |
DisclosureSEC source: 0001562180-21-003441 · primarydocument.xml · nonDerivative · entry 1 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 371,497 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $52.58 to $53.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 05, 2021 Filed Feb 16, 2022 00:21 UTC | Axonics, Inc. AXNX · Entity 86004 | GiftCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001499 · primarydocument.xml · nonDerivative · entry 3 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,635 Read SEC document |
| February 05, 2021 Filed Feb 16, 2022 00:21 UTC | Axonics, Inc. AXNX · Entity 86004 | GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001499 · primarydocument.xml · nonDerivative · entry 2 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,635 Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 01:50 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionPerformance-Based Restricted Stock Units · Derivative | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-000757 · primarydocument.xml · derivative · entry 7 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending December 31, 2020, and provided the reporting person remains in continuous service through January 30, 2021. The awards were earned at 200% of the target number on January 31, 2021. F1 · derivative.exercise_price: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending December 31, 2020, and provided the reporting person remains in continuous service through January 30, 2021. The awards were earned at 200% of the target number on January 31, 2021. F1 · derivative.exercise_date: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending December 31, 2020, and provided the reporting person remains in continuous service through January 30, 2021. The awards were earned at 200% of the target number on January 31, 2021. F1 · derivative.expiration_date: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending December 31, 2020, and provided the reporting person remains in continuous service through January 30, 2021. The awards were earned at 200% of the target number on January 31, 2021. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 01:50 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 952 | $52.12 | $49,616.24 |
DisclosureSEC source: 0001562180-21-000757 · primarydocument.xml · nonDerivative · entry 4 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,096 F2 · kind: Shares of Issuer's common stock sold to cover the reporting person's tax obligation in connection with the conversion of the Performance-Based Restricted Stock Units disclosed herein. F4 · price: This transaction was executed in multiple trades at prices ranging from $52.04 to $52.28. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 01:50 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 12,675 | $51.36 | $651,045.04 |
DisclosureSEC source: 0001562180-21-000757 · primarydocument.xml · nonDerivative · entry 3 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 457,048 F2 · kind: Shares of Issuer's common stock sold to cover the reporting person's tax obligation in connection with the conversion of the Performance-Based Restricted Stock Units disclosed herein. F3 · price: This transaction was executed in multiple trades at prices ranging from $51.03 to $52.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 01:50 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionCommon Stock | 33,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-000757 · primarydocument.xml · nonDerivative · entry 2 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 469,723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending December 31, 2020, and provided the reporting person remains in continuous service through January 30, 2021. The awards were earned at 200% of the target number on January 31, 2021. Read SEC document |
| January 31, 2021 Filed Feb 3, 2021 01:50 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantPerformance-Based Restricted Stock Units · Derivative | 42,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-000757 · primarydocument.xml · derivative · entry 6 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 42,500 shares Expires not disclosed F6 · security: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2021 and provided the reporting person remains in continuous service through January 31, 2022. F6 · derivative.exercise_price: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2021 and provided the reporting person remains in continuous service through January 31, 2022. F6 · derivative.expiration_date: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2021 and provided the reporting person remains in continuous service through January 31, 2022. Read SEC document |
| January 31, 2021 Filed Feb 3, 2021 01:50 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantPerformance-Based Restricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-000757 · primarydocument.xml · derivative · entry 5 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F5 · security: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2023, and provided the reporting person remains in continuous service through January 31, 2023. F5 · derivative.exercise_price: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2023, and provided the reporting person remains in continuous service through January 31, 2023. F5 · derivative.expiration_date: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2023, and provided the reporting person remains in continuous service through January 31, 2023. Read SEC document |
| January 31, 2021 Filed Feb 3, 2021 01:50 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-000757 · primarydocument.xml · nonDerivative · entry 1 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 436,389 Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 01:08 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionPerformance-Based Restricted Stock Units · Derivative | 27,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-000565 · primarydocument.xml · derivative · entry 3 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,173 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2020 and provided the reporting person remains in continuous service through December 31, 2020. F1 · derivative.exercise_price: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2020 and provided the reporting person remains in continuous service through December 31, 2020. F1 · derivative.exercise_date: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2020 and provided the reporting person remains in continuous service through December 31, 2020. F1 · derivative.expiration_date: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2020 and provided the reporting person remains in continuous service through December 31, 2020. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 01:08 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 7,842 | $53.58 | $420,147.70 |
DisclosureSEC source: 0001562180-21-000565 · primarydocument.xml · nonDerivative · entry 2 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,389 F2 · kind: Shares of Issuer's common stock sold to cover the reporting person's tax obligation in connection with the conversion of the Performance-Based Restricted Stock Units disclosed herein. F3 · price: This transaction was executed in multiple trades at prices ranging from $53.14 to $53.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 01:08 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionCommon Stock | 27,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-000565 · primarydocument.xml · nonDerivative · entry 1 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2020 and provided the reporting person remains in continuous service through December 31, 2020. Read SEC document |
| January 08, 2021 Filed Feb 16, 2022 00:21 UTC | Axonics, Inc. AXNX · Entity 86004 | GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001499 · primarydocument.xml · nonDerivative · entry 1 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,635 Read SEC document |
| November 12, 2020 Filed Nov 17, 2020 02:22 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 5,625 | $32.45 | $182,531.25 |
DisclosureSEC source: 0001437749-20-024047 · rdgdoc.xml · nonDerivative · entry 1 COHEN RAYMOND W · CIK 0001258288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,763 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.36 to $32.60, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 05, 2020 Filed Oct 8, 2020 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-20-020869 · rdgdoc.xml · nonDerivative · entry 1 COHEN RAYMOND W · CIK 0001258288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,388 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests on the twelve-month anniversary of the grant date. Read SEC document |
| September 15, 2020 Filed Feb 13, 2021 00:12 UTC | Axonics, Inc. AXNX · Entity 86004 | GiftCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-001142 · primarydocument.xml · nonDerivative · entry 3 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,606 Read SEC document |
| August 18, 2020 Filed Feb 13, 2021 00:12 UTC | Axonics, Inc. AXNX · Entity 86004 | GiftCommon Stock | 45,490 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-001142 · primarydocument.xml · nonDerivative · entry 2 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,606 Read SEC document |
| August 11, 2020 Filed Aug 12, 2020 00:32 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 11,033 | $42.78 | $471,947.61 |
DisclosureSEC source: 0001562180-20-005394 · primarydocument.xml · nonDerivative · entry 5 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 397,058 F1 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on June 7, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $42.42 to $43.08. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 11, 2020 Filed Aug 12, 2020 00:32 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 8,808 | $42.05 | $370,406.35 |
DisclosureSEC source: 0001562180-20-005394 · primarydocument.xml · nonDerivative · entry 4 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 408,091 F1 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on June 7, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $41.42 to $42.415. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 11, 2020 Filed Aug 12, 2020 00:32 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 5,159 | $40.95 | $211,282.20 |
DisclosureSEC source: 0001562180-20-005394 · primarydocument.xml · nonDerivative · entry 3 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,899 F1 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on June 7, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $40.41 to $41.325. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 07, 2020 Filed Aug 12, 2020 00:32 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 3,367 | $42.75 | $143,924.10 |
DisclosureSEC source: 0001562180-20-005394 · primarydocument.xml · nonDerivative · entry 2 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422,058 F1 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on June 7, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $42.6125 to $42.99. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 07, 2020 Filed Aug 12, 2020 00:32 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 16,633 | $41.82 | $695,658.59 |
DisclosureSEC source: 0001562180-20-005394 · primarydocument.xml · nonDerivative · entry 1 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,425 F1 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on June 7, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $41.525 to $42.28. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 16, 2020 Filed Jul 17, 2020 23:38 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 25,000 | $39.65 | $991,267.50 |
DisclosureSEC source: 0001562180-20-005180 · primarydocument.xml · nonDerivative · entry 4 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 442,058 F1 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on June 7, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $39.41 to $39.685. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 23:38 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 900 | $39.94 | $35,943.48 |
DisclosureSEC source: 0001562180-20-005180 · primarydocument.xml · nonDerivative · entry 3 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 467,058 F1 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on June 7, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $39.92 to $39.97. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 23:38 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 15,472 | $39.61 | $612,804.15 |
DisclosureSEC source: 0001562180-20-005180 · primarydocument.xml · nonDerivative · entry 2 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 467,958 F1 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on June 7, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $38.92 to $39.90. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 23:38 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 8,628 | $38.55 | $332,579.20 |
DisclosureSEC source: 0001562180-20-005180 · primarydocument.xml · nonDerivative · entry 1 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 483,430 F1 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on June 7, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $37.905 to $38.90. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 14, 2020 Filed Jul 16, 2020 01:55 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 25,000 | $36.49 | $912,272.50 |
DisclosureSEC source: 0001562180-20-005129 · primarydocument.xml · nonDerivative · entry 3 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 492,058 F1 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on June 7, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $36.114 to $36.625. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 13, 2020 Filed Jul 16, 2020 01:55 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 200 | $41.10 | $8,220.00 |
DisclosureSEC source: 0001562180-20-005129 · primarydocument.xml · nonDerivative · entry 2 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 517,058 F1 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on June 7, 2020. Read SEC document |
| July 13, 2020 Filed Jul 16, 2020 01:55 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 24,800 | $40.34 | $1,000,541.12 |
DisclosureSEC source: 0001562180-20-005129 · primarydocument.xml · nonDerivative · entry 1 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 517,258 F1 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on June 7, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $40.00 to $40.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 28, 2020 Filed Feb 13, 2021 00:12 UTC | Axonics, Inc. AXNX · Entity 86004 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-001142 · primarydocument.xml · nonDerivative · entry 1 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 455,096 Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 22:00 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionStock Option (Right to Buy) · Derivative | 41,224 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001562180-20-002629 · primarydocument.xml · derivative · entry 4 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,776 Underlying: Common Stock · 41,224 shares Expires 2028-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vest over a period of four years. 42,000 of the shares subject to the option vested on March 30, 2018 and the remainder vest at a rate of 1/36th per month commencing on March 30, 2019, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 22:00 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 6,955 | $21.48 | $149,389.92 |
DisclosureSEC source: 0001562180-20-002629 · primarydocument.xml · nonDerivative · entry 3 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 542,058 F1 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on September 25, 2019. F3 · price: This transaction was executed in multiple trades at prices ranging from $21.30 to $21.63. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 22:00 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 34,269 | $20.87 | $715,248.86 |
DisclosureSEC source: 0001562180-20-002629 · primarydocument.xml · nonDerivative · entry 2 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 549,013 F1 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on September 25, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.30 to $21.295. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 22:00 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionCommon Stock | 41,224 | $1.63 | $67,195.12 |
DisclosureSEC source: 0001562180-20-002629 · primarydocument.xml · nonDerivative · entry 1 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 583,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2020 Filed Feb 19, 2020 01:32 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001562180-20-001321 · primarydocument.xml · derivative · entry 3 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,000 Underlying: Common Stock · 10,000 shares Expires 2028-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option vest over a period of four years. 42,000 of the shares subject to the option vested on March 30, 2018 and the remainder vest at a rate of 1/36th per month commencing on March 30, 2019, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable. Read SEC document |
| February 13, 2020 Filed Feb 19, 2020 01:32 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 10,000 | $33.21 | $332,065.00 |
DisclosureSEC source: 0001562180-20-001321 · primarydocument.xml · nonDerivative · entry 2 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 542,058 F1 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on September 25, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $32.74 to $33.38. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 13, 2020 Filed Feb 19, 2020 01:32 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionCommon Stock | 10,000 | $1.63 | $16,300.00 |
DisclosureSEC source: 0001562180-20-001321 · primarydocument.xml · nonDerivative · entry 1 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 552,058 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2020 Filed Feb 4, 2020 02:06 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionPerformance-Based Restricted Stock Units · Derivative | 16,667 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-000792 · primarydocument.xml · derivative · entry 2 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.expiration_date: All of the Performance Based Restricted Stock Units vested on January 30, 2020. Read SEC document |
| January 30, 2020 Filed Feb 4, 2020 02:06 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionCommon Stock | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-000792 · primarydocument.xml · nonDerivative · entry 1 COHEN RAYMOND W · CIK 0001258288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625,058 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.